Resident-to-resident aggression is common in nursing homes. Here’s how we can improve residents’ safety

The Coroners Court of Victoria is undertaking an inquest into the deaths of eight aged care residents across six facilities, over a nine-month period in 2021.

Powered by WPeMatico

Better planning can reduce sickness absence among shift workers

Jarno Turunen, senior specialist at the Finnish Institute of Occupational Health and M.Sc. (Econ), has investigated the effects of shift work characteristics on the sickness absence of shift workers in his doctoral dissertation at the Jyväskylä University School of Business and Economics, Finland.

Powered by WPeMatico

Long-lasting HIV prevention shot headed toward approval

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

Powered by WPeMatico

Single-dose CAR-T therapy potentially curative in multiple myeloma

A multi-institutional study led by the Icahn School of Medicine at Mount Sinai reports one-third of patients with relapsed or refractory multiple myeloma remained in remission for at least five years following a single infusion of the CAR-T cell therapy cilta-cel.

Powered by WPeMatico

AIIMS INI SS July 2025: Stage-II Departmental Assessment Schedule out, check details

New Delhi- Through a notification, the All India Institute of Medical Sciences (AIIMS) New Delhi has announced the dates for the Departmental Assessment (Stage-II) in the respective applied course for AIIMS & PGIMER Chandigarh seat under the Institute of National Importance Super-Speciality (INISS) Online (CBT) Test for DM and MCh Courses for the July 2025 Session.

As per the notification, the Departmental Assessment (Stage-II) for all shortlisted candidates will be conducted from 10th June 2025 to 12th June 2025. The assessment dates specific to each department will be communicated separately. Meanwhile, details regarding the video conferencing platform and the timing of the assessment will be sent to candidates via email by the respective departments.

Below are the detailed schedule-

SCHEDULE

S.NO

SUBJECT

DATE OF DEPARTMENTAL ASSESMENT

1

Addiction Psychiatry

10 June 2025

2

Cardiac Anaesthesia and critical care

10 June 2025

3

Cardiology

12 June 2025

4

Cardiovascular Radiology & Endovascular Interventions

11 June 2025

5

Child and Adolescent Psychiatry

12 June 2025

6

Clinical Hematology

10 June 2025

7

Clinical Immunology and Rheumatology

10 June 2025

8

Clinical Pharmacology

10 June 2025

9

Critical Care Medicine/Intensive Care

11 June 2025

10

Endocrinology

11 June 2025

11

Forensic Radiology & Virtual Autopsy

11 June 2025

12

Gastroenterology

11 & 12 June 2025

13

Hematopathology

10 June 2025

14

High Altitude Medicine

11 June 2025

15

Infectious Diseases

10 June 2025

16

Interventional Radiology

12 June 2025

17

Medical and Forensic Toxicology

11 June 2025

18

Medical Genetics

11 June 2025

19

Medical Oncology

10 June 2025

20

Neonatology

10 June 2025

21

Nephrology

11 June 2025

22

Neuro-Anaesthesiology & Neurocritical Care

10 June 2025

23

Neuroimaging and Interventional Neuroradiology

12 June 2025

24

Neurology

10 June 2025

25

Neuropathology

12 June 2025

26

Onco-Anesthesia

11 June 2025

27

Pediatric Cardiology

12 June 2025

28

Paediatric Emergency Medicine

12 June 2025

29

Paediatric Endocrinology

11 June 2025

30

Paediatric Gastroenterology and Hepatology

10 June 2025

31

Pediatric Nephrology

10 June 2025

32

Pediatric Neurology

12 June 2025

33

Pediatric Pulmonology & Intensive Care

12 June 2025

34

Paediatric Pulmonology

12 June 2025

35

Paediatrics Critical Care

12 June 2025

36

Pain Medicine

10 June 2025

37

Pulmonary, Critical Care & Sleep Medicine

10 & 11 June 2025

38

Therapeutic Nuclear Medicine

10 June 2025

39

Paediatric Anaesthesiology

12 June 2025

40

Psychosomatic Medicine

11 June 2025

41

Trauma Anaesthesia & Acute Care

11 June 2025

42

Tropical Infectious Diseases & Infection Control

10 June 2025

43

Breast, Endocrine and General Surgery

10 June 2025

44

C.T.V.S

12 June 2025

45

G.I. Surgery

12 June 2025

46

Gynaecologic Oncology

10 June 2025

47

Head Neck Surgery and Oncology/Head Neck Surgery

11 June 2025

48

Joint Replacement & Reconstruction

12 June 2025

49

Minimal Access Surgery & General Surgery

11 June 2025

50

Neuro Surgery

11 June 2025

51

Paediatric Orthopedics

12 June 2025

52

Pediatric Surgery

12 June 2025

53

Plastic and Reconstructive Surgery

10 June 2025

54

Renal Transplant Surgery

12 June 2025

55

Surgical Oncology

11 June 2025

56

Trauma Surgery and Critical Care

11 June 2025

57

Urology

11& 12 June 2025

58

Vitreoretinal Surgery

10 June 2025

59

Spine Surgery

10 June 2025

60

Reproductive Medicine & Surgery

11 June 2025

To view the notification, click the link below

https://medicaldialogues.in/pdf_upload/aiims-announces-stage-ii-departmental-assessment-schedule-for-june-2025-exams-to-be-held-from-june-10-289959.pdf

Powered by WPeMatico

Consumer Court slaps Rs 35 lakh compensation for medical negligence in C-sections

Trichy: Two separate cases of alleged medical negligence during caesarean section procedures at private healthcare facilities in Trichy have resulted in compensation awards totalling Rs 35 lakh, following rulings by the District Consumer Disputes Redressal Commission.

As per a recent media report in The Times of India, the first case, adjudicated on May 22, involved a 26-year-old woman who alleged she had received spinal anaesthesia on the wrong nerve during a C-section performed in September 2022. Following the procedure, she began suffering from ongoing physical impairments, including difficulty walking, sitting, and performing routine activities. Later scans showed the presence of disc bulges.

The commission found that the spinal anaesthesia had been negligently administered, concluding that the healthcare professionals involved were guilty of deficiency in service.

Accordingly, the commission directed the concerned parties to pay Rs 30 lakh as compensation for the harm caused, and Rs 15,000 to cover legal costs, reports TOI.

Also Read: Disability Due to Medical Negligence, Hospital, Doctors Slapped Rs 20 Lakh Compensation

The second case, a woman who underwent a C-section in February 2018 at a local Trichy clinic experienced chronic abdominal discomfort that persisted well after the surgery. It wasn’t until nearly a year later that diagnostic imaging identified the cause: a 26×6 mm hypoechoic tract in the subcutaneous layer due to a retained non-absorbable Prolene suture. She subsequently underwent corrective surgery in April 2019, involving scar excision and sinus tract exploration to remove the suture material.

In its ruling dated May 23, the consumer commission determined that the attending medical staff had failed to ensure complete closure of the surgical wound and did not provide sufficient post-operative care. This was deemed a case of medical negligence and deficiency in service under the Consumer Protection Act, 2019.

As a result, the clinic was ordered to compensate the complainant with Rs 5 lakh for medical negligence, Rs 52,000 to cover medical and surgical costs, and Rs 10,000 as litigation expenses.

Powered by WPeMatico

Fact Check: Can water with lemon and alkaline salts act as cancer killing alkaline water?

An Instagram post claims that water with lemon and alkaline salts act as cancer killing alkaline water. The claim is FALSE.

Claim

In an Instagram post, it is claimed that water with lemon and alkaline salts act as cancer killing alkaline water. The post by the user vitolyzeofficial is captioned as, “Cancer Killing alkaline water. Squeeze 1-2 lemons, or more if you want to make it more potent, add 1/2 to 2 scoops of alkaline salts (phour salts from phmiracle products in USA or avocadoninja. com in EU) drink up straight as a super concentrated shot or add to 1 litre water as a hydrating drink

Drink 2-3 times daily

Illness is not natural — wellness is 💯 natural. Start using natural molecules to heal, recover & rejuvenate!

The reel can be accessed here

Fact Check

The claim is False. While lemon offers several health benefits, it is inherently acidic and not alkaline. There is no scientific evidence or medical consensus supporting the claim that combining lemon with alkaline salts can treat or cure cancer.

What is Cancer?

Cancer is a condition in which certain cells in the body begin to grow uncontrollably and have the potential to spread to other areas. It can occur in almost any part of the body, which is made up of trillions of cells. Typically, cells grow and divide in a regulated way to produce new cells when needed, and old or damaged cells die to make room for new ones. However, in cancer, this normal process is disrupted, leading to the unchecked growth and division of abnormal or damaged cells.

These abnormal cells can form lumps called tumors, which may be benign (non-cancerous) or malignant (cancerous). Malignant tumors have the ability to invade nearby tissues and spread to other parts of the body through a process known as metastasis, creating secondary tumors in distant organs. While many cancers form solid tumors, some types, like leukemia (blood cancers), do not.

Can Cancer Be Cured/Killed?

Cancer cannot be completely cured or killed or eradicated, but it can go into remission. Remission refers to a state where the cancer has responded positively to treatment, and the signs of cancer have significantly diminished or disappeared. In remission, no further treatment may be necessary for the time being. However, it is important to note that it is rare to consider cancer as completely cured, as there is always a possibility of recurrence.

American Cancer Society says, “Whether a person’s cancer can be cured depends on the type and stage of the cancer, the type of treatment they can get, and other factors. Some cancers are more likely to be cured than others. But each cancer needs to be treated differently. There isn’t one cure for cancer.”

What are the Nutritional Benefits Of Lemon?

Lemon, is an evergreen tree species native to South Asia, particularly North East India. This fruit offers notable health benefits, with a peeled lemon containing 17 calories and 22 calories when including the peel. One tablespoon of lemon juice provides 3 calories, while a quarter cup delivers 31% of the daily recommended vitamin C, 3% of folate, and 2% of potassium, totaling 13 calories. Beyond its use in food and nutrition, lemon is valued for its medicinal properties. It aids in weight management, helps regulate blood pressure, and supports conditions like osteoporosis, insomnia, asthma, nausea, vomiting, travel sickness, acne, throat infections, scurvy, and fever. Additionally, lemon helps maintain the body’s pH balance, offering a variety of health benefits through its juice, leaf oil, citric acid, alkaloids, and other nutrients.

What are Alkaline Salts?

Alkaline salts act as effective substitutes for costly sodium hydroxide (NaOH) treatments. They break down lignocellulosic structures by cleaving ester and glycosidic bonds, modifying lignin, swelling cellulose, and improving cellulose digestibility. These salts also enhance the release of fermentable sugars by removing acetyl groups from xylan polymers.

Can water with lemon and alkaline salts act as cancer killing alkaline water?

The claim that water with lemon and alkaline salts can act as “cancer-killing alkaline water” is unsupported by scientific evidence. Lemon water has some health benefits but it is acidic in nature. Further, there is no reliable scientific proof that lemon and alkaline salts can cure or kill cancer.

Lemon offers various health benefits, including antimicrobial, antifungal, and anti-inflammatory properties, as demonstrated in a study conducted by Paramita Jana et al. The research highlights these potential therapeutic effects, emphasizing lemon’s ability to combat infections and reduce inflammation.

Lemon is highly acidic in nature, as noted in a review by Bernard Tiencheu et. al., and it contributes to the acidic characteristics of the juice blend, with its pH ranging from 3.40 to 4.90, indicating its significant acidic properties.

Yet another study led by W.M. Otang et. al. noted that the lemon is a potential source of vitamin C.

There is no scientific evidence or established medical consensus supporting the use of alkaline salts in cancer prevention or treatment. A systematic review published in Nutrition and Metabolism concluded that, despite widespread promotion of the alkaline diet and alkaline water in popular media and by marketers, there is a significant lack of clinical research validating these claims. The review found no credible evidence linking dietary acid load or alkaline water with the onset or management of cancer.

Lemon is known for its health-promoting properties and is acidic in nature. However, current scientific evidence or medical consensus does not validate the claim that lemon and alkaline salts have the ability to kill or cure cancer.

Talking to the Medical Dialogues Fact Check Team, Dr Darshana Rane, Consultant Medical Oncology, HCG Cancer Centre, Borivali said, “The relationship between alkaline water and cancer is a topic of ongoing debate. Some proponents claim that alkaline water can help prevent or treat cancer by neutralizing acidity in the body. However, there is limited scientific evidence to support these claims.

The human body has a natural pH regulation system, maintaining a slightly alkaline pH level (around 7.35–7.45) despite dietary influences. Cancer is a multifaceted disease involving genetic, environmental, and lifestyle factors.

Potential Benefits and Limitations

– Some alkaline waters may contain antioxidants, which can help reduce oxidative stress.

– Adequate hydration is essential for overall health.

– However, there is insufficient evidence to support alkaline water as a cancer treatment or prevention method.

It is important to prioritize established cancer prevention strategies, such as maintaining a balanced diet, engaging in regular exercise, and avoiding known carcinogens. If you have concerns about cancer prevention or treatment, consult a healthcare professional for personalized advice.

Dr Riddhijyoti Talukdar, Consultant Radiation Oncology, HCG Cancer Centre, Borivali, further said, “Although it might be true as per some lab-based studies that cancer cells thrive in acidic environment, drinking alkaline water in no way can decrease the growth of cancer.

1. Our stomach contains the strongest acid (Hydrochloric acid) and drinking any amount of alkali will be immediately neutralized.

2. The pH of the body is tightly regulated with a complex biochemical process. Alkalosis or Acidosis (Increase in or decrease in the body pH beyond the normal limit of 7.35 to 7.45) are both serious conditions requiring critical management in ICU.

Consuming alkaline water or salts like ‘phour salt’ orally will not alter the pH of the body. Cancer cells may have an innate mechanism to induce acidic environment in the vicinity. Drinking alkaline water, while may not be poisonous, and in some cases help with hyperacidity, using it as treatment can delay timely evidence-based interventions, and may indirectly responsible for progression of an early stage cancer to an advanced cancer which has a less chance of cure. For prevention, here is something you can try instead- high fibre diet, regular exercise, decrease in intake of preservatives, refined sugar, stopping the of use of alcohol and tobacco.

Medical Dialogues Final Take

The claim that that water with lemon and alkaline salts act as cancer killing alkaline water. Lemon water can provide health benefits but it’s acidic, not alkaline. There’s no scientific evidence or medical consensus to support that lemon with alkaline salts can cure or kill cancer.

Hence, the claim is FALSE.

Powered by WPeMatico

MBBS fees for 5 years instead of 4.5: MCC tells DY Patil Medical College to clarify its fee structure

New Delhi: Following the National Medical Commission’s recent directive to the Directorate of Medical Education (DME) to investigate the MBBS fee issue at Pune-based DY Patil Medical College, the Medical Counselling Committee (MCC) has now sought clarification from the institute in this regard.

On Thursday, 05.06.2025, Dr. B. Srinivas, the Deputy Director General (MEC) and Member of the Medical Counselling Committee (MCC), wrote to the Dean of the Institute, requesting clarification on the vague fee structure at the medical college and the fifth-year MBBS fees charged to medical students. 

This comes after Dr. Divyansh Dwivedi, who has been raising the matter to different government authorities, complained about the fee structure of DY Patil Medical College on the CPGRAMS portal, alleging that the fee structure is not transparent. He had also sought to know what the institute meant by the fifth installment, as the duration of the MBBS course was 4.5 years.

Addressing this, Dr. Srinivas mentioned in the letter, “This is in reference to the subject matter mentioned above. The complainant Dr. Divyansh Dwivedi has complained about the vague fee structure at your institute. The complainant has stated that the fee structure is not transparent and is different from the one uploaded on the MCC portal. Also, the complainant has sought clarification regarding fifth year fees or fifth instalment and what is the nature of this instalment.”

Also Read: MBBS fees for 5 years instead of 4.5: DY Patil Medical College Pune under NMC scanner

“The complainant has also stated that the institute has withheld original documents of the candidate including DRP Certificate. The copy of the complaint is being attached herein for your reference,” the letter further mentioned.

Accordingly, asking the medical college to provide clarification on this, the letter further mentioned, “Keeping in view of the above, you are requested to kindly clarify regarding the fee structure applicable at your institute and also upload the precise fee structure (year wise) at our MCC portal. The undersigned requests your good office to kindly provide us with the existing details at the earliest so that the same may be communicated to the complainant. This issues with approval of the Competent Authority.”

Medical Dialogues had earlier reported that after receiving numerous complaints/grievances from students alleging that D Y Patil Medical College Hospital and Research Centre was collecting MBBS fees for 5 years instead of 4.5 years, the Undergraduate Medical Education Board (UGMEB) of NMC asked the Directorate of Medical Education (DME), Maharashtra to investigate the matter and take proper action, if required. DME Maharashtra had been directed to clarify if any medical college in Maharashtra is charging full fees for the 5th year instead of charging only for 4.5 years, the duration of the MBBS course.

In the letter dated 01.05.2025, addressed to the DME, NMC had also clarified that these complaints received from the students shall be reviewed during the approval process for annual renewal of the concerned medical college for the Academic Year 2025-2026. However, the Commission, at the same time, had clarified that while it issues the required regulations or guidelines, the responsibility of implementation was of the concerned institute and the State authorities.

Recently, NMC asked the Directorate of Medical Education (DME), Maharashtra, to expedite its investigations into these allegations and send a compliance report immediately to the Commission for taking necessary action.

Also Read: MBBS Fee Issue at DY Patil Medical College: NMC tells DME to Expedite Investigation

Powered by WPeMatico

Bayer arm secures exclusive worldwide rights to develop, commercialize clinical-stage WRN Inhibitor

San Diego: Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, has announced it has secured exclusive worldwide rights to develop and commercialize the clinical-stage Werner helicase (WRN) covalent inhibitor VVD-214 (RO7589831), strengthening and complementing its oncology development pipeline.

VVD-214 was discovered and developed under an exclusive worldwide collaboration and license agreement initiated between Vividion and Roche in 2020. Vividon utilizes innovative discovery technologies to unlock difficult-to-drug targets with strong disease-links, and to develop small molecule precision therapeutics for devastating cancers and immune disorders.

Preliminary data from a first-in-human study presented at the recent American Association for Cancer Research (AACR) Annual Meeting showed that VVD-214 is well tolerated and has promising signs of activity. Vividion will continue the clinical development of VVD-214 within the company’s pipeline of innovative investigational therapeutics for cancers and immune disorders.

WRN is a DNA repair enzyme and a highly sought-after synthetic lethal target for treatment of cancers with microsatellite instability (MSI). By inhibiting WRN, VVD-214 aims to cause lethal DNA damage in cancers with high microsatellite instability while minimizing harm to healthy cells.

“Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion,” said Aleksandra Rizo, M.D., Ph.D., Chief Executive Officer of Vividion. “We are eager to progress development of this compound, building on the encouraging clinical data we’ve seen to date, as part of our mission to transform treatment for patients with cancer and other serious diseases.”

The Phase I clinical trial (NCT06004245) is evaluating VVD-214 as a monotherapy and in combination with pembrolizumab as a treatment option for patients with solid tumors that display high MSI or deficient mismatch repair (dMMR) including but not limited to colorectal, endometrial, ovarian and gastric cancers. Treatment options for these patients today are limited, and a majority will relapse or become refractory to immune checkpoint inhibitors. The initial data, recently presented at AACR by Timothy Yap, M.B.B.S., Ph.D., clinical investigator and professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, showed early signals of efficacy for VVD-214 in a range of solid tumor types with high MSI. 

“VVD-214 is showing promising potential to improve treatment options for patients suffering from MSI-high cancers, a population with high unmet medical need,” said Christian Rommel, Ph.D., Global Head of Research and Development at Bayer’s Pharmaceuticals Division. “It underscores the ability of Vividion’s chemoproteomics technology to identify and advance new treatment opportunities for challenging and intractable diseases, and will be a valuable addition to the company’s portfolio.”

Vividion also has ongoing Phase I trials evaluating an oral KEAP1 activator in solid tumors, an oral STAT3 inhibitor in solid and hematologic malignancies, and an oral RAS-PI3Kα inhibitor in advanced solid tumors. The company is advancing multiple innovative drug discovery programs toward the clinic and has a growing pipeline of opportunities emerging in early discovery in the fields of oncology and immunology leveraging its chemoproteomics platform.

Powered by WPeMatico

Artemis Hospital, Medulance launches 5G-enabled ambulances

Gurugram: In a step towards transforming emergency care, Artemis Hospitals, Gurugram, in collaboration with Medulance healthcare, unveiled 5G-enabled advanced ambulances on Wednesday, a hospital official said. 

The initiative is set to transform emergency care by harnessing the power of next-gen 5G connectivity, AI-driven diagnostics, and real-time telemedicine to ensure a quicker and more effective response during critical moments, the official said.

According to an official statement, the launch of this advanced ambulance is part of Artemis Hospital’s dedication to adopting the latest technology to enhance healthcare services, reports PTI.

The 5G-enabled ambulance is more than just a vehicle; it’s a mobile extension of the emergency department, fully equipped and supercharged with 5G, it said.

Also Read:Cancer Care: Over 600,000 International patients travel to India every year

It lets you have video consultations in real time, send live vital signs, and get expert advice. This integration helps hospitals get ready for patients and speed up clinical decisions, the statement added.

Dr Devlina Chakravarty, Managing Director, Artemis Hospitals, said, “This initiative will set a new benchmark for emergency care in India, ensuring that every patient receives timely and accurate care, no matter where they are, news agency PTI reported.

“In a country where millions of lives are lost due to delays in medical treatment, this technology is a game-changer,” she said.

“This initiative represents a leap forward in emergency medical response. By integrating the speed and reliability of 5G, we’re able to provide real time, data driven medical assistance, drastically improving patient outcomes,” said Dr Vishal Arora, Chief of Business Transformation & Operational Excellence, Artemis Hospitals.

“It’s not just about faster ambulances, it’s about better healthcare from the moment the emergency occurs, all the way until the patient is stabilized in the emergency room”, he added.

In emergencies like heart attacks, strokes, or trauma, time is very important. With 5G, important information like heart rate, oxygen levels, and blood pressure is sent from the ambulance to the hospital right away, allowing for quick and informed care. The ambulance with 5G and AI keeps an eye on and analyzes patient data in real time, the statement added.

Pranav Bajaj, Co-Founder and CEO, Medulance Healthcare, said, “We extend our heartfelt thanks to the Artemis team for their trust, collaboration, and vision in driving this pioneering step forward.”

Also Read:World TB Day: Artemis Hospital organizes public awareness workshop

Powered by WPeMatico